1. Comparing Azithromycin to Amoxicillin in the Management of Uncomplicated Severe Acute Malnutrition in Burkina Faso: A Pilot Randomized Trial.
- Author
-
O'Brien, Kieran S, Sié, Ali, Dah, Clarisse, Ourohiré, Millogo, Ouedraogo, Moussa, Boudo, Valentin, Arzika, Ahmed, Lebas, Elodie, Nyatigo, Fanice, Godwin, William, Kelly, J Daniel, Arnold, Benjamin F, and Oldenburg, Catherine E
- Subjects
Humans ,Malnutrition ,Weight Gain ,Amoxicillin ,Azithromycin ,Anti-Bacterial Agents ,Treatment Outcome ,Pilot Projects ,Child ,Child ,Preschool ,Infant ,Burkina Faso ,Severe Acute Malnutrition ,Pediatric ,Clinical Research ,Comparative Effectiveness Research ,Infectious Diseases ,Clinical Trials and Supportive Activities ,Nutrition ,Medical and Health Sciences ,Tropical Medicine - Abstract
Azithromycin is a promising alternative to amoxicillin in the management of uncomplicated severe acute malnutrition (SAM) as it can be administered as a single dose and has efficacy against several pathogens causing infectious disease and mortality in children under 5. In this pilot trial, we aimed to establish the feasibility of a larger randomized controlled trial and provide preliminary evidence comparing the effect of azithromycin to amoxicillin on weight gain in children with uncomplicated SAM. We enrolled children 6-59 months old with uncomplicated SAM at six healthcare centers in Burkina Faso. Participants were randomized to a single dose of azithromycin or a 7-day course of amoxicillin and followed weekly until nutritional recovery and again at 8 weeks. Apart from antibiotics, participants received standard of care, which includes ready-to-use therapeutic food. Primary feasibility outcomes included enrollment potential, refusals, and loss to follow-up. The primary clinical outcome was weight gain (g/kg/day) over 8 weeks. Outcome assessors were masked. Between June and October 2020, 312 children were screened, 301 were enrolled with zero refusals, and 282 (93.6%) completed the 8-week visit. Average weight gain was 2.5 g/kg/day (standard deviation [SD] 2.0) in the azithromycin group and 2.6 (SD 1.7) in the amoxicillin group (mean difference -0.1, 95% CI -0.5 to 0.3, P = 0.63). Fewer adverse events were reported in the azithromycin group (risk ratio 0.50, 95% CI 0.31-0.82, P = 0.006). With strong enrollment and follow-up, a fully powered trial in this setting is feasible.
- Published
- 2022